Shows
Medical Affairs UnscriptedThe Intersection between New Product Planning and Medical Affairs with Cathy Symonds, PhDIn this episode of Medical Affairs unscripted, Peg Crowley-Nowick, PhD, MBA, Senior Advisor, Medical Affairs Consulting at Lumanity, and Cathy Symonds, PhD, Program Lead and Head of New Product Planning at Arbor Biotechnologies, engage in an insightful discussion about the evolving role of new product planning and its intersection with Medical Affairs. Peg and Cathy explore the strategic importance of new product planning in the lifecycle of medical products, emphasizing how early commercial strategy is essential for successful development and market entry. They discuss various frameworks and best practices, including the creation of a Target Product Profile (TPP), which h...
2025-06-2550 min
The MM+M PodcastThe Strategies for Success Podcast | Lumanity: Navigating the future: How Lumanity is helping clients deliver on the promise of innovative medicinesJoin us as two thought leaders from Lumanity delve into the evolution of their organization and how they are approaching the transformative impact of AI for their clients in today’s environment. Discover what surprised them most on their AI journey and what they are most excited about moving forward.
Step into the future of health media at the MM+M Media Summit on October 30th, 2025 live in NYC! Join top voices in pharma marketing for a full day of forward-thinking discussions on AI, streaming, retail media, and more. Explore the latest in omnichannel strategy, personalization, me...
2025-06-1025 minMedical Affairs UnscriptedRare Insights: Navigating Medical Affairs in Rare Disease Launches with Eva Gallagher, PhD, CNMAPIn the latest episode of Medical Affairs unscripted, Peg Crowley-Nowick, PhD and Senior Advisor, Medical Affairs Consulting at Lumanity, engages in a compelling conversation with Eva Gallagher, PhD, CNMAP, VP, Head of Medical Affairs at Agios Pharmaceuticals. They explore the strategic role of Medical Affairs in the rare disease space, discussing best practices for building effective teams, engaging diverse stakeholders, and leveraging digital tools for education. Eva’s journey and success in the field offer a blueprint for how Medical Affairs can drive impactful change and enhance patient outcomes. The discussion delves into the significance of s...
2025-05-2844 minMedical Affairs UnscriptedPodcast Bytes - From Tweets to Trends: Leveraging Social Media for Medical Affairs Insights with Jamie DoggettIn this episode of Medical Affairs unscripted, Peg Crowley-Nowick, PhD, MBA, President of Medical Affairs Consulting at Lumanity, discusses the critical role of social media listening in healthcare with Jamie Doggett, Associate Director of Social Media Insights and Analytics at Lumanity. They explore the insights obtained from Jamie's whitepaper, Transforming Scientific Conversations: Adapting to a New Era of Healthcare Social Media. Jamie highlights how unprompted online conversations among healthcare professionals and patients can reveal critical insights for pharmaceutical companies. They delve into the usage of platforms like Twitter, Bluesky, and Threads, emphasizing the need for agility in adapting communication st...
2025-04-1830 min
A Healthy Dose of HumourWhat patients REALLY thinkHumour can ease anxiety in patients, but is it always appropriate? Join our panel of patients and healthcare marketing experts as they discuss the art of using humour and building stronger connections with your audience. A masterclass in patient-centricity. Listen to Susan Daniels, Vice President, Patient Strategy & Engagement at Lumanity; Jane Shanaham, a patient advocate for multiple sclerosis; Brian Coane, Partner of Leith Health; and Ria Lina, award-winning comedian. Hosted on Acast. See acast.com/privacy for more information.
2025-04-0833 minMedical Affairs UnscriptedRealizing Value through Effective Medical Affairs Operations with Keith PooleJoin Peg Crowley-Nowick, PhD, MBA, President of Medical Affairs Consulting at Lumanity, in this episode of Medical Affairs Unscripted as she engages with Keith Poole, Executive Director and Head of Medical Excellence & Impact Enhancement at Merck KGaA, Darmstadt, Germany. They delve into the critical role of Medical Operations in fostering a high-performance culture within organizations. The discussion covers the strategic collaboration between medical operations teams and Medical Directors, focusing on advisory board meetings, strategy, budgeting, and analysis and communication of actionable insights. Furthermore, they examine the qualities of effective leadership in Medical Affairs and outline the steps to build a...
2025-03-2745 minMedical Affairs UnscriptedCreating Synergies by Integrating Across Medical Affairs with Caroline Ojaimi, PhDIn this episode of Medical Affairs Unscripted, Peg Crowley-Nowick, PhD, MBA, President of Medical Affairs Consulting at Lumanity, speaks with Caroline Ojaimi, PhD, Head of Global Scientific Communications, Congresses, and External Engagement at Takeda Oncology. Dr. Ojaimi shares her passion for Medical Affairs and provides insights into strategically redesigning organizational structures to enhance agility, efficiency, and cross-functional collaboration. Their discussion covers the importance of dedicated congress leadership, the role of external engagement in shaping scientific communications, and how integrated approaches drive better stakeholder interactions. A key focus of the conversation is the increasing emphasis on...
2025-03-0643 minMedical Affairs UnscriptedPodcast Bytes - Use of GenAI in Medical Publications with Tim Becker, PharmD, RPh In this Medical Affairs unscripted Podcast Byte, Peg Crowley-Nowick, PhD, MBA, President of Medical Affairs Consulting at Lumanity, discusses the recently released insights report: Expert Perspectives on the Use of Generative AI in Medical Publication with her colleague, Tim Becker, PharmD, RPh, EVP, Creative Scientific Solutions at Lumanity. Their discussion sheds light on the safe and proper use of Generative AI in medical publications, addressing key concerns such as hallucinations, data privacy, and the need for transparency and accountability. They also explore the future impact of Generative AI on medical communication agencies and their relationships with journals. Although Generative AI can...
2025-02-2425 minMedical Affairs UnscriptedEstablishing Strategic Connections to Accelerate Clinical Trials with Smitha Sivaraman, PhD, MBA In this episode of Medical Affairs Unscripted, Peg Crowley-Nowick, PhD, MBA, President of Medical Affairs Consulting at Lumanity, engages in an enlightening discussion with Smitha Sivaraman, PhD, MBA, Vice President of Medical Affairs at Verastem Oncology. Their discussion highlights the growing trend of integrating Medical Affairs into the Clinical Development process, and how this integration can streamline development when executed properly. Dr. Sivaraman shares her insights on the expectations for Medical Affairs teams working alongside clinical development, the ideal timing for their involvement, and how their role should progress over time. They also discuss the necessary skills and qualities...
2025-01-3142 min
PharmaTalkRadioInvestment Trends in Immuno-OncologySummary:In this podcast, recorded at the February 2024 IO360º summit, biopharma, finance and investment experts discuss the fundability features of IO biotechs, and the current pharma needs that will drive potential partnerships or M&A. Moderater:Axel Hoos, MD, PhD, Former CEO, Scorpion TherapeuticsPanelists: Irina Margine, PhD, Principal, Biotech Private Equity, Wellington ManagementKhalil Barrage, Managing Partner, Invus GroupJeffrey Bockman, PhD, EVP, Oncology and Virology Practices, LumanityEmmett Schmidt, MD, PhD, VP, Clinical Oncology, External Collaborations, MerckGayatri Varma, PhD, Executive Direct...
2025-01-2238 min
Outcomes RocketPart 2: Conquer Launch Complexity: Strategies For Pharma Success with Keitel Suri, Vice President at LumanitySuccessful pharmaceutical launches depend on collaboration and visibility across stakeholders, ensuring alignment on goals, progress, and issues.In the second part of this two-episode special, Keitel Suri, Vice President at Lumanity, discusses the Ignite platform, a launch readiness tool designed to streamline and accelerate pharmaceutical brand launches. He highlights the challenges of managing launches with numerous stakeholders and the need for real-time, global-to-local visibility, needs that Ignite addresses by providing multiple views, fostering collaboration, and prioritizing tasks. Keitel emphasizes the limitations of traditional methods like Excel spreadsheets, noting that dedicated tech solutions can offer more, and introduces...
2025-01-2019 min
Outcomes RocketPart 1: Conquer Launch Complexity: Strategies For Pharma Success with Keitel Suri, Vice President of Launch Excellence at LumanityLaunching a pharmaceutical brand is a complex and high-stakes endeavor, requiring a smarter and faster approach supported by technology to ensure timely decision-making.In the first part of this amazing conversation, Saul Marquez introduces "IGNITE," an innovative launch readiness tool designed by former pharma leaders aimed at enhancing launch planning and collaboration in the pharma industry. In a conversation with Keitel Suri, Vice President of Launch Excellence at Lumanity, insights are shared on navigating pharmaceutical launches effectively, emphasizing the importance of preparation and readiness amidst the evolving landscape. They discuss the critical role of frameworks and platforms...
2024-12-2018 minMedical Affairs UnscriptedInsights for Building a Rockstar MSL Team with Cathy Andorfer, PhDIn this episode of Medical Affairs Unscripted, Peg Crowley-Nowick, PhD, MBA, President of Medical Affairs Consulting at Lumanity, welcomes Cathy Andorfer, PhD, the national Director of Field Medical for Tourmaline Bio, and author of "The Art of Excellence: Build a Rockstar Career as a Medical Science Liaison and Beyond." Their conversation explores the vital role of medical affairs, emphasizing the importance of strategic vision, continuous learning, and effective communication within the team. Cathy shares her experiences and insights on leadership, stressing the necessity of repetition and clarity in setting objectives. She believes that consistent reminders and clear priorities are...
2024-11-2747 min
Therapeutic Science and StrategyKey Oncology Takeaways from ESMO 2024During this episode, Lumanity experts Rob Rawlinson and Kate Goacher discuss insights and takeaways from their recent attendance at the 2024 European Society for Medical Oncology (ESMO) conference. Their conversation covers a variety of topics, including: The importance of the patient and including the patient voice in drug development The way that Artificial Intelligence (AI) could impact and innovate cancer care Insights on a selection of early-phase extensive-stage small-cell lung cancer (ES-SCLC) assets
2024-10-1609 min
Therapeutic Science and StrategyEmbracing the Pediatric Voice from Childhood Through Young Adulthood: Elevated Insights that Fuel Your Brands' NeedsIn this episode, we talk about the concerns, misconceptions, and the value of engaging directly with and including the pediatric voice in market research
2024-09-3028 min
The "Elevate" by MAPS PodcastIntegrated Evidence Generation Planning: Top Challenges for Medical Affairs TeamsAs the sources of data and technologies needed to make sense of data expand, opportunities exist for further integrating Real-World Evidence (RWE) and Health Economics and Outcomes Research (HEOR) alongside traditional approaches when planning data generation activities to support new product registration, access, and use. Here we speak with experts from Lumanity about the Integrated Evidence Generation Planning (IEGP) process and how to overcome the barriers to success.
2024-09-0323 minMedical Affairs UnscriptedGenerative AI Unleashed: Revolutionizing Innovation and Efficiency in Medical Affairs with Jane Carroll, MS, BSN In this episode of Medical Affairs Unscripted, Peg Crowley-Nowick, PhD, MBA, President of Medical Affairs Consulting at Lumanity, welcomes Jane Carroll, MS, BSN, Vice President of Global Strategy and Operations at Moderna. They discuss the evolving role of medical affairs and the impact of generative AI, specifically ChatGPT, on the field. Jane shares her experiences leveraging AI as a copilot to enhance efficiency and innovation in medical affairs. They delve into the potential of AI to speed up publication processes and reduce biases, ultimately impacting patient care positively. The conversation highlights AI as a tool to augment, not replace...
2024-07-2339 minA Healthy Dose of HumourResuscitation room riffs and a prostate cancer named PaulHear from cancer survivor Tatum De Roeck on the surprising ways that laughtermanifests during the patient journey. From answering questions like ‘is it ok to everjoke about cancer’ to telling stories about her ‘cancer diagnosis party’ we’ll explore thesubstantial and surprising health benefits of humour. Tatum is joined by Susan Daniels,Vice President, Patient Strategy & Engagement at Lumanity; Tatum De Roeck a patient;Vic Milne, Head of Strategy at Leith; Anthony Alderson, Director of the Pleasance; andaward-winning comedian and Healthy Dose of Humour hos...
2024-06-1242 min
The MM+M PodcastThe A100 Playbook Podcast | Lumanity: Lumanity's second year on the top 100, a podcast sponsored by LumanityHow Lumanity is accelerating and optimizing access to medical advances through a time of rapid market transformation. Step into the future of health media at the MM+M Media Summit on October
30th, 2025 live in NYC! Join top voices in pharma marketing for a full
day of forward-thinking discussions on AI, streaming, retail media, and
more. Explore the latest in omnichannel strategy, personalization, media
trust, and data privacy—all under one roof. Don’t wait—use promo code
PODCAST for $100 off your individual ticket. Click here to register!
AI Deciphered is back—live in New York City this November 13th.Join
leade...
2024-06-1124 minMedical Affairs UnscriptedPodcast Bytes - The Digital Transformation of Medical Affairs with Dan Hennessy, PhD Medical Affairs is going through a digital transformation. What this means, what it will look like, and what value it will bring to pharmaceutical and biotech companies is still unknown. In this third episode of our short form podcast series, we discuss this topic with Dan Hennessy, PhD. As the Vice President of Medical Affairs at Merus N.V., he has a wealth of Medical Affairs experience and insights. This conversation brings us further along in trying to understand the changes that are coming to the industry, and more specifically how it may affect clinical trial enrollment and engagement.
2024-05-2808 min
Therapeutic Science and StrategyCommunications Testing Research: Unlock the Power of Behaviour ChangeIn our latest Lumanity bitesize podcast, we explore how to avoid the common challenges and pitfalls encountered in communication testing research, and share best practices in applying a behavioural science lens to bring about stakeholder behaviour change. Our discussion includes: The importance of evaluating concepts using the right criteria Generating maximum impact using clear and simple ads that cut through the noise Being vigilant that the insights being used are robust and precise - and ultimately fuel better campaign decisions The importance of engaging with the target audience early and ensuring campaigns...
2024-05-1516 minMedical Affairs UnscriptedThe Value of Medical Affairs – Strategic Thinking and Continuity from Clinical Development to Commercialization and Beyond With Jodi Smith, PhD In this episode of Medical Affairs Unscripted, Peg Crowley-Nowick, PhD, MBA, President of Medical Affairs Consulting at Lumanity, and Jodi Smith, PhD, the Global Medical Strategy Lead in Thoracic Oncology at Pfizer, discuss the value of Medical Affairs. While they agree that there’s a cost associated with bringing Medical Affairs into the early development of a drug, they see a clear and measurable benefit, from accelerated enrollment to having a solid foundation for commercialization. Through their many years in different roles within Medical Affairs, they know that to achieve these benefits, organizations need to have the right team mem...
2024-04-3045 minMedical Affairs UnscriptedExcellence in Leadership – International Women’s Day Special With Aree Cheshire, PhD, and Amber Gilbert, MBA Curiosity, empathy, authenticity, strength. Good leaders express many key characteristics and come in all shapes and sizes. In this special International Women’s Day episode of Medical Affairs Unscripted, Peg Crowley-Nowick, PhD, MBA, President of Medical Affairs Consulting at Lumanity, Aree Cheshire, PhD, VP of Client Strategy in UK Communications at Lumanity, and Amber Gilbert, MBA, Global Practice Lead for Value, Access & Outcomes at Lumanity, meet to discuss excellence in leadership. During their conversation they touch on whether good leadership qualities are innate or learned, how to balance being a leader versus a “do-er”, and how to approach leadership differentl...
2024-03-0841 minMedical Affairs UnscriptedThe Patient Impact in Drug Development and Value Demonstration with Len Lichtenfeld, MD, MACP Now, more than ever, the patient voice is being heard by the pharmaceutical industry. In this episode, Peg Crowley-Nowick, PhD, MBA, President of Medical Affairs Consulting at Lumanity, and Len Lichtenfeld, MD, MACP meet to discuss the ways patients are providing advisement in drug development and valuation. After hearing about Len’s extensive experience, they delve into the new regulatory changes coming to pharma and biotech that will require the patient experience to be taken into consideration during the drug development process. They conclude by discussing how the patient experience is having an impact on the valuation of new drug...
2024-02-2934 min
Therapeutic Science and StrategySupporting Rare Disease Communities In this special podcast episode in honor of Rare Disease Day 2024, Angela Wheeler, President of Insight at Lumanity and Dr. Karin Hoelzer, Director of Policy and Regulatory Affairs at the National Organization for Rare Disorders (NORD), discuss opportunities for pharmaceutical companies to work with and support rare disease communities. Learn how NORD is strengthening collaboration between pharmaceutical companies and rare disease communities, and examples of the positive impact that can be made when pharmaceutical companies, organizations like NORD, and patient advocates join together. Listen to the full episode to hear Angela ask Karin some important...
2024-02-2829 min
Michael and Mom Talk CancerMichael and Mom Talk Rare Disease Day: Episode 38, Living with a Rare Disease (or 2!)Michael and Mom talk cancer (specifically hepato splenic t-cell lymphoma) and chronic graft versus host disease, the two rare diseases that Michael lives with. Our dear friends at Lumanity asked us to answer a few questions and share our two perspectives, unique experiences, living with a rare disease diagnosis, on this special day, Rare Disease Day, February 29th, 2024. Join Michael and Mom for a spirited, real conversation on the challenges and the surprising benefits, as well.
2024-02-2719 minMedical Affairs UnscriptedThe Role of the MSL in Clinical Trial Enrollment with Dan Hennessy PhD Having a clinical trial that is properly supported and engaged is no easy feat, but accomplishing this can greatly improve the success of your asset. In this episode, Peg Crowley-Nowick, PhD, MBA, President of Medical Affairs Consulting at Lumanity, and Dan Hennessy PhD, Vice President of Medical Affairs at Merus N.V., meet for a second time to discuss MSL and stakeholder engagement. They delve more specifically into the key role that Medical Affairs plays in accelerating and improving clinical trial enrollment and highlight how to use MSLs and a Field Medical team in different ways to ensure that yo...
2024-02-0136 min
Therapeutic Science and StrategyMaking Social Media Listening Insights Count: Live or Let DieIn this podcast episode, we explore the rich potential of social media listening (SML) insights, and how, when interpreted and acted on, they can have a significant impact on commercial decision-making. Hear from Lumanity experts as they bring SML to life using several real world examples. Topics include: How the agility, flexibility and insights from SML research are being harnessed to help improve commercial decisions How SML best complements traditional research and data The value of SML in reaching conversation leaders, HCPs and patient advocates The value for detecting commonalities and patterns, as well...
2024-01-2426 min
Therapeutic Science and StrategyEnsuring the Responsible and Meaningful Use of Generative AI in Healthcare Market ResearchIn this podcast episode, we explore the fascinating world of artificial intelligence and its impact on the healthcare industry, as well as the ever evolving realm of research and its potentially transformative power on decision making. Hear from Lumanity experts Damian Eade, Head of Digital Insights and Analytics, Gemma Spickernell, Director of Behavioral Science, and Andrew Wood, Head of Behavioral Science as they discuss how to navigate the balance between the benefits of AI while ensuring accuracy and integrity in research. This thought-provoking conversation considers the potential of Generative AI, it's application and implications in...
2023-12-0718 minMedical Affairs UnscriptedPodcast Bytes - The Digital Transformation of Medical Affairs with Christian Dimaano, PhD, MPH Medical Affairs is going through a digital transformation. What this means, what it will look like, and what value it will bring to pharmaceutical and biotech companies is still unknown. In this third episode of our short form podcast series, we discuss this topic with Christian Dimaano, PhD, MPH. As the VP, Head of Medical Affairs at Kinnate Biopharma, he has a wealth of Medical Affairs experience and insights. This conversation brings us further along in trying to understand the changes that are coming to the industry.
2023-11-1610 min
Therapeutic Science and StrategyThe Importance of RWE Strategy PlanningThere are incredible synergies with joint HEOR and Real World Evidence (RWE) projects, but there are also unique challenges. In this podcast episode, The Importance of RWE Strategy Planning, Ann-Marie Chapman, Nikita Jeswani, Meena Venkatachalam, and Alex Thorel discuss the use cases and planning for RWE, identifying appropriate RWE, and RWE trends. Listen to this podcast to learn: · Key considerations, steps, and recommendations in identifying appropriate data sources · Where RWD and RWE are leveraged most across the product lifecycle · The length of time it takes to initiate an RWE study · The common mi...
2023-11-0230 minMedical Affairs UnscriptedUntapped Potential of Social Media Listening in Medical Affairs with Damian EadeSocial media listening is an area with great untapped potential in the pharmaceutical industry. In this episode, Peg Crowley-Nowick, PhD, MBA, President of Medical Affairs Consulting at Lumanity, and Damian Eade, Managing Director, Social Analytics, Insight at Lumanity, discuss how a Medical Affairs team approaches social media listening differently than a commercial team. They review the differences between traditional key opinion leaders and digital thought leaders as well as discuss the impact these “digital influencers” have in the social media landscape. They talk through insight collection and learning about the patient experience through social media and how these insights can...
2023-10-2738 minMedical Affairs UnscriptedBuilding US, EU, & Asia PAC Field Medical Teams during Early Development with Christian Dimaano, PhD, MPH A thoughtfully and carefully built Medical Affairs team, and in particular, a Field Medical team can enhance study enrollment and serve as a foundation for future commercialization. In this episode, Peg and Christian Dimaano, PhD, MPH, VP, Head of Medical Affairs at Kinnate Biopharma, discuss the differences between building a Medical Affairs team in the US compared to building teams in the EU or Asia PAC, and the ideal timing for bringing field medical onboard. They review the pros and cons of outsourcing a field team versus building internally and highlight the different skill sets needed for teams at...
2023-09-2841 minMedical Affairs UnscriptedLearning and Development to Propel an Organization Forward with Adeola Davis, PHD, MPA, and Mary Winkles, PharmD An effective learning and development program can be transformative for a Medical Affairs organization. In this discussion, Peg, Adeola Davis, PHD, MPA, Director of Learning Development at Arcadia Pharmaceuticals, and Mary Winkles, PharmD, Global Director, Medical Affairs Training and Capability at Vertex Pharmaceuticals, break down what it takes to build a successful learning and development program and how to measure its success. They highlight when organizations should build a learning and development program and how to think about scalability. Additionally, they discuss how effective and efficient training can greatly increase employee retention as well as help an organization speak...
2023-08-3147 minMedical Affairs UnscriptedPodcast Bytes - The Digital Transformation of Medical Affairs with John Yee, MD, MPH Medical Affairs is going through a digital transformation. What this means, what it will look like, and what value it will bring to pharmaceutical and biotech companies is still unknown. In this second episode of our short form podcast series, we discuss this topic with Dr. John Yee. As the former CMO at Sobi, Dr. Yee has a wealth of Medical Affairs experience and insights. This conversation brings us further along in trying to understand the changes that are coming to the industry.
2023-07-2816 minMedical Affairs UnscriptedWhy PharmDs are a good fit for Medical Affairs with Lumanity Medical Affairs Consulting PharmDs In this special episode of Medical Affairs Unscripted, Peg Crowley-Nowick, PhD interviews three of Lumanity Medical Affairs Consulting PharmDs, Stephanie Wong, George Shyu, and Chris Maclafferty. They discuss the different paths they took from earning their degree to joining the pharmaceutical industry as well as the additional training and knowledge they felt were required to be successful in Medical Affairs. They breakdown the skills and expertise that PharmDs can bring to a Medical Affairs organization and how they chose to work in a consulting role rather than in a more typical role as a Medical Science Liaison (MSL) or...
2023-06-2741 min
The MM+M PodcastAgency 100 Studio Session: How Lumanity is accelerating and optimizing access to medical advances: The origin, mission, and vision of a rising industry powerhouse, a podcast presented by LumanityJoin us for an insightful interview with Lumanity, making their debut among the MM+M Top 100 agencies this year. Discover how Lumanity has emerged as a global leader in a highly competitive market. Listen in to hear what’s behind the new branding and their recipe for success that is equal parts talent and technology. Step into the future of health media at the MM+M Media Summit on October
30th, 2025 live in NYC! Join top voices in pharma marketing for a full
day of forward-thinking discussions on AI, streaming, retail media, and
more. Explore the latest in omnichannel strategy, pe...
2023-06-2120 min
Therapeutic Science and StrategyLaunch Excellence Alchemy: Managing Strategic Risk Strategic risk is often overlooked within the pharmaceutical industry. There’s a perception that someone else is picking up the risk ball. Or there is more of a focus on internal risks, with little thought to the larger external factors that can have a significant impact on your launch. We see common risks arise from competitor launches, multi-indication launches, and supply chain issues. Unmitigated risks can lead to costly delays. So, what can you do to identify the risks for your asset launch and successfully mitigate them? In our latest Launch Excellence Alchemy po...
2023-06-0528 minMedical Affairs UnscriptedInvesting in Medical Affairs with John Yee, MD, MPH Whether your drug is in an early development phase or in the lifecycle management phase, it is important to know when and how to invest in Medical Affairs. In their discussion this month, Peg and John Yee, MD, MPH and former CMO at Sobi, focus on the value of and the critical need to invest in Medical Affairs. They see Medical Affairs as the “bridge” across all functions and that it sits at the intersection of medicine, science, and business. They highlight the need to communicate and engage with the commercial side of the organization while building a Medical Affa...
2023-05-3038 minMedical Affairs UnscriptedPodcast Bytes - The Digital Transformation of Medical Affairs with Janet Loesberg, PharmD Medical Affairs is going through a digital transformation. What this means, what it will look like, and what value it will bring to pharmaceutical and biotech companies is still unknown. Over the remainder of 2023, we’ll be releasing additional short form podcasts, podcast bytes, where we discuss this topic with our guests. Janet Loesberg, PharmD, SVP of Global Medical Affairs at Blueprint Medicine, is our first guest and we greatly appreciate her insights. We look forward to delving into this topic on future episodes.
2023-05-1918 minTherapeutic Science and StrategyLaunch Excellence Alchemy: Mindset, Leadership, and the Value of a 'Third Voice'We know that effective collaboration across cross-functional and global/local launch teams is one of the critical elements to launch success – but teams often struggle to develop the right behaviors that foster a truly collaborative culture. Leadership styles too play a vital role, with research directing us away from ‘leading from the front’, towards a model that champions interdependent leadership and shared accountability. In the second episode of our series on launch excellence, we explore how: Heroic leadership styles can hinder collaboration when launching a product Looking at your own behaviors and mindset can create the bigges...
2023-05-0928 minTherapeutic Science and StrategyPossible Implications of the Inflation Reduction Act for Oncology Products and StakeholdersIn this episode, Dr. Nancy McGee and Rob Rawlinson discuss potential implications of the Inflation Reduction Act (IRA) legislation that was passed in the U.S. in 2022. This episode covers: An overview of the IRA in relation to healthcare The potential impacts for oncology patients, manufacturers, and oncologists The impact of the legislation outside of the U.S. Speakers: Nancy McGee, JD, MPH, DrPH, Senior Vice President, Health Policy & Public Payers, Lumanity Rob Rawlinson, Director, Oncology Insights Lead, Lumanity ©2023 Lumanity Inc.
2023-05-0219 minMedical Affairs UnscriptedMedical Affairs Leadership – Breaking Through Barriers to Success with Janet Loesberg, PharmD Are you leading or building a Medical Affairs organization? This month Peg had a great conversation with Janet Loesberg where they discussed leadership and the barriers to success in Medical Affairs. Janet Loesberg, PharmD, Senior Vice-President of Global Medical Affairs at Blueprint Medicine, and a biotech board member, brings many years of experience, holding a variety of leadership positions in the pharmaceutical industry. She delivers great advice and perspectives focused on leading in Global and US Medical Affairs, building a team with the right person matched to the right role, and ensuring communication across the team. Dr. Peg Crowley-Nowick...
2023-04-2836 minTherapeutic Science and StrategyLaunch Excellence Alchemy: Who Cares WinsDuring the launch of a new medicine, there is so much focus on the intellectual strategy, that it's easy to sideline thoughts about "How are we going to collaborate as a team to make this happen?" But statistics show that strong teamwork can deliver up to 3x more shareholder value. Investing time in good cross-functional collaboration is not just a nice-to-have, it's a must-have for successful launch teams. In the first episode of our series on launch excellence, we explore the following: How strong internal collaboration delivers optimal launch outcomes Why...
2023-04-0328 minMedical Affairs UnscriptedDistinguishing between Tracking and Performance Metrics in Medical Affairs with Randy Krauss, PhD Defining metrics and KPIs for demonstration of value is a significant challenge for leaders in Medical Affairs. During this episode of Medical Affairs unscripted, Dr. Crowley-Nowick speaks with Dr. Randy Krauss, Head of Metrics, Analytics, & Performance in Global Clinical Operations at Merck. They discuss the key ideas, lessons learned, and recommendations that have come from Dr. Krauss’s work in clinical operations and how those ideas can be translated into the Medical Affairs space. The objective of this podcast is to stimulate discussion about measurements and value in a more effective way.
2023-03-2846 minMedical Affairs UnscriptedAchieving Global Field Medical Excellence with Robin Winter-Sperry, MD During the latest episode of our Medical Affairs unscripted podcast, Dr. Crowley-Nowick speaks with Dr. Robin Winter-Sperry, Former Global Field Based Medical Lead at Ipsen Biopharmaceuticals. The conversation covers: - What Field Based Medical entails and the roles of Medical Science Liaisons and Field Medical Directors across the globe - What skills are required of field based medical teams today and what the future holds - The unique requirements of those managing a field based medical team - How training can vary significantly across different regions - How to measure the value of f...
2023-02-2844 min
Ticking BoxesRecognising the importance of Corporate and Social Responsibility in today’s workplace.Today we are joined by Clare Eason who is the Global Head of Corporate and Social Responsibility at the company Lumanity, who are in the healthcare space. Back in 2008 Clare joined the company (then known as Cello Health) as an Executive Assistant working with CEO'S. With her background of dealing with Mental Health providers and her passion for wellbeing, culture and charity she was the perfect choice to drive forward CSR. After undertaking a specific project for CSR, the role evolved culminating in Clare's latest position as Global Head of CSR, responsible for more than 1250 em...
2023-02-131h 24Medical Affairs UnscriptedOur Medical Affairs Journey Continues | Zipher becomes Lumanity with Dr. Peg Crowley-NowickDuring this episode of Medical Affairs unscripted, the roles are reversed and Dr. Crowley-Nowick speaks with guest interviewer Dennis Crowley (of The Entrepreneur's Story podcast) about Zipher continuing its journey in Medical Affairs as a part of Lumanity. They discuss Zipher’s history, the acquisition, the integration, and how Zipher, now Lumanity, fits into the larger company structure. Dr. Crowley-Nowick explains how being a part of Lumanity is beneficial to our clients while including some of the new product offerings and capabilities of the expanded team. They reflect on how smoothly and seamlessly the integration has been and discuss so...
2023-01-2718 minMedical Affairs UnscriptedMedical Affairs - Bridging Cross-Functional Partnerships with Holly Schachner, MDDuring this episode of Medical Affairs unscripted, Dr. Crowley-Nowick continues the conversation with Holly Schachner, MD, SVP, Clinical Development at North Sea Therapeutics, discussing how the landscape has changed since they last spoke, two and a half years ago, as the pandemic was just unfolding. They also discuss how Medical Affairs continues to play an integral role in bridging across functions, bringing key stakeholders to the table, so that getting needed therapies to patients remains their central mission.
2022-12-0629 min
Therapeutic Science and StrategyDiscussion with the CEO and CMO of ImCheckIn this podcast series, Joel Sandler, Principal, Cancer Cell Therapy Lead at Lumanity, sits down to talk about relevant and important content. In this sixth episode, Joel sits down with the CEO and CMO of ImCheck Therapeutics to discuss: Company origins, focus, and fundraising performance to date Role of butyrophilins (BTNs) as an novel therapeutic target to boost antitumor immunity Performance of ICT01, Imcheck’s clinical-stage lead program targeting BTN3A in gamma-delta T-cells Positioning and commercial strategy in the post-PD1 solid-tumor landscape Episode Guests: Pierre d’Epenoux, CEO, ImCheck Therapeutics Paul Frohna, CMO...
2022-11-1620 min
You're Blank, What Now?Episode 52: “You’re Beating Cancer 3 Times & Living Life, What Now?” with Andrea OttaianoIn this episode, myself and Andrea Ottaiano talk about her journey of thriving with cancer since her first diagnosis in 2007… Andrea uses her life timeline along with her children’s ages as a gauge to “live in the moment”, never taking time for granted and living out her life with no regrets. She is currently living with cancer in her bones/chest wall and is on treatment. She sees the need to share her experience with the people that need it most, the other people diagnosed with cancer and the families that love them. She wants to help people reframe and smart...
2022-10-191h 12
Therapeutic Science and StrategyTailored Treatment Algorithms, Liquid Biopsy, and Personalized Medicine In this podcast series, Joel Sandler, Principal, Cancer Cell Therapy Lead, sits down to talk about relevant and important content. In this fifth episode, Joel sits down with Brian Leyland-Jones, MB BS, PhD, CMO, National Foundation for Cancer Research and Peter Kuhn, PhD, Dean’s Professor of Biological Sciences, Professor of Biological Sciences, Medicine, Biomedical Engineering, Aerospace and Mechanical Engineering and Urology, to explore: Historical perspective on personalized approaches to cancer treatment Liquid biopsy as a means to facilitate adaptive treatment regimens tailored to individual cancers Vision of where the field is goi...
2022-09-1326 min
Therapeutic Science and StrategyA Look Beyond: Scientific, Clinical, and Commercial Considerations in Post-Checkpoint Solid Tumor SettingsIn this podcast series, Joel Sandler, Principal, Cancer Cell Therapy Lead, sits down to talk about relevant and important content. In this fourth episode, Joel sits down with Jeff Bockman, Executive Vice President and Head of Oncology at Lumanity, and Michael Curran, PhD, Associate Professor, Department of Immunology, The University of Texas, MD Anderson Cancer Center, to explore: • The effort to develop agents for the CPI resistant/refractory patients. Where do we biologically and clinically stand with this concept? • Whether IO remains a “spaghetti against the wall” approach, and what are we doing/can we do to...
2022-07-1132 min
The MM+M PodcastGuidemark Health: The specialty agency enters a new phase, a podcast presented by LumanityIn this MM+M sponsored podcast, Marc Iskowitz, executive editor, MM+M, spoke with Michael Parisi, global president and Marissa Poli, head of workflow at Lumanity Creative Strategy and Engagement about how Guidemark Health, an agency that specializes in oncology and rare disease, is entering a new phase. Step into the future of health media at the MM+M Media Summit on October
30th, 2025 live in NYC! Join top voices in pharma marketing for a full
day of forward-thinking discussions on AI, streaming, retail media, and
more. Explore the latest in omnichannel strategy, personalization, media
trust, and data privacy—all un...
2022-06-2717 minMedical Affairs UnscriptedField Medical Team Optimization with Christina Tankersley, PharmDWith the pharmaceutical industry becoming more and more heavily competitive, knowing how to conduct an insightful and multidimensional assessment of your Medical Science Liaison (MSL) team to identify gaps and hire the right MSLs to not only accelerate a corporate competitive advantage, but also to cultivate the natural diversity of a proper team for internal peer-to-peer development and external stakeholder rapport is more critical than ever. With an extensive and influential career in Medical Affairs (MA) at Sanofi Pasteur spanning more than two decades starting in the field and now the current Senior Director of the Field Medical Team i...
2022-06-0145 min
Therapeutic Science and StrategyChanging the Narrative: The Story of an Ultra-rare Cancer PatientIn this podcast series, Joel Sandler, Principal, Cancer Cell Therapy Lead, sits down to talk about relevant and important content. In this third episode, Joel sits down with Michael 'Mitch' Petrick, anaplastic thyroid cancer patient, to explore: Mitch's background and his rare form of thyroid cancer His journey from initial diagnosis (which he made!) through to referral and treatment Some thoughts about the drug development process and system from the perspective of someone in need of new solutions Lessons for drug manufacturers and healthcare providers ©2023 Lumanity Inc.
2022-05-3125 min
Therapeutic Science and StrategyCAR-T in Solid Tumors: A Cancer Progress Sneak PeekIn this podcast series, Joel Sandler, Principal, Cancer Cell Therapy Lead, sits down to talk about relevant and important content. In this second episode, Joel sits down with Shivani Srivastava, PhD, Assistant Professor Human Biology Division, Fred Hutchinson Cancer Research Center, to explore: Key challenges to addressing solid tumors with cell therapy Recent developments (technology, scientific understanding) that are lowering these barriers The ultimate promise offered by cell therapy for solid tumor patients (what a ‘win’ looks like) Thoughts about what can and will be achieved, and over what timeframe ©2023 Lumanity Inc.
2022-04-2522 min
Therapeutic Science and StrategyNot So Rare: Win-wins in Ultra-orphan DiseasesIn this podcast series, Joel Sandler, Principal, Cancer Cell Therapy Lead, sits down to talk about relevant and important content. In this first episode, Joel sits down with Michael Parisi, CEO of Guidemark, and Michael Rice, Vice President, Head of Advanced Therapeutics, to explore: How uncovering NSCLC and SMA genetics led to record-speed options for patients with rare subtypes How the patient advocacy groups enabled translation How the provider infrastructure is evolving to meet the need for genetic precision What pharma brought upon entering and how the lessons shape their and field’s outlook What’s next...
2022-02-2618 minMedical Affairs UnscriptedMedical Affairs Capabilities to Create a Competitive Advantage with Tamas Suto, MD, PhDLeading Medical Affairs (MA) organizations have begun to strategically redefine their team’s requisite executional capabilities to enhance and tailor frontline engagement initiatives, to improve the impact of knowledge development (insights and evidence generation), and to further solidify their position as a vital leader rather than a support function within the biopharmaceutical industry. These executional capabilities ultimately accelerate the time to market, creating a competitive advantage as well as (and most importantly) maximizes the number of patients reached with life-saving treatments. Dr. Tamas Suto is passionately dedicated to improving the lives of patients and public health as ev...
2022-02-2440 minMedical Affairs UnscriptedGathering, Understanding, and Leveraging Insights with Muriel Siadak, PACOur host Peg Crowley-Nowick, PhD, MBA, Founder & President of Zipher Medical Affairs and Muriel Siadak, PAC, Senior Medical Director at Seagen Inc., spotlight the ever-increasing value and impact of insights on product strategy, positioning, and tactics. As Medical Affairs (MA) teams are now more than ever asking deeper, multifaceted questions to gain insights about the drivers of patient and healthcare professional decisions, Ms. Siadak, shares her vast experience in MA to help us explore the importance of ensuring that insights are appropriately gathered, disseminated to and discussed with internal stakeholders, and leveraged cross functionally. Contact Zipher at w...
2021-11-2334 minMedical Affairs UnscriptedMedical Affairs Launch Readiness: Building, Planning & Execution with Chris Keir, MD, MSDrs. Crowley-Nowick and Keir set the stage for a successful launch as they consider the key components of a MA Team and their contributions on the road to launch and beyond, from the formation and training of the Medical Science Liaison Team (MSLs) to the early inclusion of Medical Information, to developing best practices for Scientific Communications while also engaging with Patient Advocacy groups as part of the planning process. They also address the importance of a robust Data Generation program with the Medical Director at the helm gaining insights and trends from these data which allows the organization...
2021-09-2836 minMedical Affairs UnscriptedExecuting Launch: Develop, Visualize, and Communicate with John Walsh, MDStarting from the clinical trials and ending with meeting the regulatory demands across various countries, bringing a product to market successfully has become increasingly difficult. Therefore, it is critical that an overall launch strategy is established and executed. Developing an integrated and comprehensive launch roadmap is the first step in preparing for launch. Delivering the Medical Affairs program on time, on target, and on budget is essential for success. A solid program management function and systems ensures that progress is monitored, measured, and communicated and adjustments to the course based on internal and external insights are clearly visible to...
2021-07-2834 minMedical Affairs UnscriptedMeasuring the Impact of Medical Affairs with Meg Heim, RN, MBAMeasuring the impact of the Medical Affairs (MA) organization is not as straightforward as it is for other functions (e.g., increase in revenue or market share for Commercial) and remains a challenge for most pharmaceutical companies today. There have historically been no simple metrics to evaluate the influence of MA, so our host Peg Crowley-Nowick, PhD, MBA, Founder & President of Zipher Medical Affairs met with Meg Heim, RN, MBA, previously Vice President, Global Head of Scientific Engagement Strategy, Operations and Program Management at Sanofi and currently President at Heim Global Consulting, to discuss a methodology she developed and...
2021-05-2628 minMedical Affairs UnscriptedMedical Affairs as a Strategic Equal and Maximizing a Virtual Launch with Zhen Su, MD, MBAMedical Affairs (MA) continues to shed its historic role as a support function and establish itself as a critical pillar alongside Commercial and Research & Development (R&D). However, shifting from independently, operating functional areas to strategic, cross-functional, business-wide partnerships remains a challenge for MA. Zhen Su, MD, MBA, the current Senior Vice President and Global Head of the Oncology Franchise for Merck KGaA, Darmstadt, Germany offers novel approaches for modernizing perspectives at an individual level regarding the role of MA, by fostering an appreciation and internal mindset of MA as a strategic, partner, while still maintaining the...
2021-03-2332 minMedical Affairs UnscriptedInternal Edition - Building a Comprehensive Data Generation Program with Julie Cahill, MDIn this Internal Edition of the Zipher Medical Affairs Unscripted podcast series, Dr. Peg Crowley-Nowick, Founder & President of Zipher Medical Affairs is joined by Zipher’s own Julie Cahill, M.D., Vice President of Consulting and Medical Director Services to continue the conversation from Episode 4: Data Generation • The Intersection Between Medical Affairs and Clinical Development by expanding further on the need to identify data gaps and how organizations can work together to consider the full scope of research that can be used to fill those gaps. Dr. Cahill, an industry expert and a board-certified general surgeon, shares how...
2020-10-2017 minMedical Affairs UnscriptedData Generation - The Intersection Between Medical Affairs and Clinical Development with Adam Schayowitz, PhD, MBAAs the Medical Affairs Unscripted podcast series continues to distinguish Medical Affairs as one of the major pillars of biopharmaceutical organizations, Dr. Peg Crowley-Nowick, Founder & President of Zipher Medical Affairs hosts Dr. Adam Schayowitz, an industry veteran and current Vice President and Medicine Team Lead at Pfizer, to discuss the intersection between Medical Affairs (medical) and Clinical Development (development) with regards to data generation as medical continues its evolution as the third pillar in industry. Dr. Crowley-Nowick draws on Dr. Schayowitz’s expertise which crosses both medical and development to get his insight on the potential impact med...
2020-09-2946 minMedical Affairs UnscriptedBuilding an Integrated Engagement Roadmap with Randi Goeckeler, MAZipher’s Medical Affairs unscripted features Randi Goeckeler, an industry expert with over 25 years of experience and most recently the Executive Director of Global Stakeholder Relations at Allergan, who discusses how to build an integrated, strategic stakeholder relations program to accelerate availability of treatments for patients and ultimately help them have better outcomes. Host Peg Crowley-Nowick, Ph.D., MBA, Founder & President of Zipher Medical Affairs invites Randi to share her insights on the challenges that organizations are facing regarding stakeholder relations and how to ensure that engagements are innovative, intentional, interconnected, and impactful. As presented in her St...
2020-08-1841 minMedical Affairs UnscriptedThe Business Objective of Medical Affairs with Holly Schachner, MDDuring this episode of Medical Affairs unscripted, Dr. Crowley-Nowick has a conversation with Holly Schachner, MD, former CMO of Specialty Medicine at Allergan to examine the business objective of Medical Affairs (MA) organizations and how MA can move closer to being identified as a strategic pillar within the life sciences industry alongside the Research & Development and Commercial organizations. Dr. Schachner, who has nearly 20 years of experience in the pharmaceutical industry after her work as a clinician and researcher, provides key insights for MA professionals on how to use their position and experience from industry and clinic to...
2020-07-2032 min
Medical Affairs UnscriptedStakeholder Engagement with Dan Hennessy, PhD, MBAPeg Crowley, Ph.D., MBA, Founder & President of Zipher Medical Affairs meets with Dan Hennessy, Ph.D., MBA, Vice President of Strategic Excellence at EMD Serono to discuss a fresh look at the complexity of the matrix of stakeholders who play a critical role in the patient care cycle, including the layers of individuals in the clinics and hospitals, in healthcare economy, and in advocacy societies. Drs. Crowley and Hennessy, who combined have about 35 years of experience in industry, address the importance of maintaining scientific exchange between the stakeholders and Medical Affairs organizations during a pandemic, which...
2020-05-2140 min